Description
Avodart (Dutasteride) Capsules 0.5 mg. №30
Composition
Active ingredient: Dutasteride 0.5 mg.
Other ingredients: (insert other ingredients here).
Mechanism of Action
Dutasteride, a 5-alpha-reductase inhibitor, decreases the production of dihydrotestosterone (DHT), a hormone contributing to prostate growth.
Pharmacological Properties
Pharmacological Effects: Dutasteride inhibits the conversion of testosterone to DHT, leading to reduced prostate volume and improved urinary symptoms in benign prostatic hyperplasia (BPH) patients.
Indications for Use
Avodart (Dutasteride) capsules are indicated for treating symptomatic BPH in men with an enlarged prostate to alleviate symptoms, lower the risk of acute urinary retention, and decrease the need for BPH-related surgery.
Contraindications
Avodart (Dutasteride) capsules are contraindicated in women and children. Pregnant women should avoid handling due to potential risks to the male fetus.
Side Effects
Common side effects may include decreased libido, impotence, and decreased ejaculate volume. Contact your healthcare provider if you experience any severe side effects.
Usage Instructions
Take Avodart (Dutasteride) capsules as directed by your healthcare provider. Swallow the capsules whole with a full glass of water. Do not chew or crush them.
Benefits Compared to Analogues
Avodart has shown efficacy in reducing prostate size, improving urinary symptoms, and lowering the risk of disease progression in men with BPH, distinguishing it from other treatments.
Suitable Patient Groups
Avodart is suitable for adult men with BPH symptoms. It is not indicated for use in women or children.
Storage and Shelf Life
Store Avodart at room temperature away from moisture and heat. Check the expiration date on the packaging and do not use after the specified date.
Packaging Description
Avodart is available in packs containing 30 capsules of Dutasteride 0.5 mg each.
Clinical Evidence and Proven Effectiveness
Clinical Trials: A randomized controlled trial published in the New England Journal of Medicine demonstrated that Dutasteride significantly reduced the risk of acute urinary retention and the need for BPH-related surgery compared to placebo.
